Tchem AGER Advanced glycosylation end product-specific receptor

Protein Summary

Description

Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides. The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847). [provided by RefSeq, May 2011]

Uniprot Accession IDs

• Q15109
• A2BFI7
• A6NKF0
• A7Y2U9
• B0V176
• Q15279
• Q3L1R4
• Q3L1R5
• Q3L1R6
• Q3L1R7
• Q3L1R8
• Q3L1S0
• Q86SN1
• Q9H2X7
• Q9Y3R3
• V5R6A3

Gene Name

• AGER

Ensembl ID

• ENST00000375055
• ENSP00000364195
• ENSG00000204305
• ENST00000375067
• ENSP00000364208
• ENST00000375069
• ENSP00000364210
• ENST00000375076
• ENSP00000364217
• ENST00000383275
• ENSP00000372762
• ENSG00000206320
• ENST00000383279
• ENSP00000372766
• ENST00000412470
• ENSP00000387853
• ENSG00000229058
• ENST00000426138
• ENSP00000415144
• ENSG00000230514
• ENST00000427822
• ENSP00000416042
• ENSG00000231268
• ENST00000432831
• ENSP00000413391
• ENSG00000237405
• ENST00000436456
• ENSP00000397227
• ENSG00000234729
• ENST00000438221
• ENSP00000387887
• ENST00000441180
• ENSP00000388462
• ENST00000441804
• ENSP00000391743
• ENST00000447921
• ENSP00000395812
• ENST00000449037
• ENSP00000400667
• ENST00000451115
• ENSP00000401068
• ENST00000453588
• ENSP00000399686
• ENST00000456918
• ENSP00000409457
• ENST00000547328
• ENSP00000448579
• ENST00000547651
• ENSP00000449708
• ENST00000548464
• ENSP00000450134
• ENST00000549758
• ENSP00000447301
• ENST00000550562
• ENSP00000446835
• ENST00000551254
• ENSP00000449226
• ENST00000551381
• ENSP00000448979
• ENST00000551827
• ENSP00000449042

Symbol

• RAGE
• RAGE
• SCARJ1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
virus perturbation	0.92
co-expressed gene	0.89
disease	0.88
protein domain	0.85
gene perturbation	0.83

Protein Classes

PANTHER Classes

Protein / Transmembrane Receptor Regulatory/adaptor Protein / Advanced Glycosylation End Product-specific Receptor

Protein / Receptor / Cytokine Receptor / Immunoglobulin Receptor Superfamily / Advanced Glycosylation End Product-specific Receptor

Protein / Defense/immunity Protein / Immunoglobulin Receptor Superfamily / Advanced Glycosylation End Product-specific Receptor

Protein / Cell Adhesion Molecule / Immunoglobulin Superfamily Cell Adhesion Molecule / Advanced Glycosylation End Product-specific Receptor

DTO Classes

Protein / Receptor / Cytokine Receptor / Immunoglobulin Receptor Superfamily / Advanced Glycosylation End Product-specific Receptor

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 1412.05   (req: < 5)

Gene RIFs: 926   (req: <= 3)

Antibodies: 781   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 1412.05   (req: >= 5)

Gene RIFs: 926   (req: > 3)

Antibodies: 781   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 47

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 17

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0